Insulin Pump Criteria: Revised Effective June 1, 2014

Payment for a continuous subcutaneous insulin external infusion pump and related supplies will be authorized for treatment of Type I diabetes. Recipients must meet either Criterion A or B as follows:

**Criterion A:** The recipient has completed a comprehensive diabetes education program and has been on a program of multiple daily injections of insulin (at least three injections per day) with frequent self-adjustments of insulin dose for at least six months prior to initiation of the insulin pump; and has documented frequency of glucose self-testing an average of at least four times per day during the two months prior to initiation of the insulin pump; and meets two or more of the following criteria while on the multiple daily injection regimen:

- Has a glycosylated hemoglobin level (HbAlc) greater than 7.0 percent;
- Has a history of recurring hypoglycemia;
- Has wide fluctuations in blood glucose levels (regardless of A1C);
- Demonstrated microvascular complications;
- Recurrent severe hypoglycemia;
- Suboptimal diabetes control (A1C exceeds target range for age);
- Adolescents with eating disorders;
- Pregnant adolescents;
- Ketosis-prone individuals;
- Competitive athletes; and
- Extreme sensitivity to insulin in younger children.

**OR**

**Criterion B:** The recipient with Type I diabetes has been on a pump prior to enrollment in Medicaid and has documented frequency of glucose self-testing an average of at least four times per day during the month prior to Medicaid enrollment.

In addition to meeting Criterion A or B above, the recipient with diabetes must be insulinopenic per the updated fasting C-peptide testing requirement, or must be autoantibody positive (e.g. islet cell autoantibodies (ICA), glutamic acid decarboxylase (GAD65), the 40K fragment of tyrosine phosphatase (IA2), insulin autoantibodies (IAA), or zinc transporter 8 autoantibodies (ZnT8)).
Updated fasting C-peptide testing requirement:

- Insulinopenia (defined as fasting C-peptide level less than or equal to 110 percent of the lower limit of normal of the laboratory’s measurement method)
- Fasting C-peptide levels will only be considered valid with a concurrently obtained fasting glucose less than 225 mg/dl
- Levels only need to be documented once in the medical record

The pump must be ordered by and follow-up care of the recipient must be managed by a physician who has familiarity with continuous subcutaneous insulin infusion (CSII) and who works closely with a team of nurses, diabetes educators and dietitians who are knowledgeable in the use of CSII.

**Non-Covered Items DMEPOS**

Continuous subcutaneous insulin external infusion pumps shall be denied as not medically necessary for all Type II diabetics, including insulin requiring Type II diabetics.

Insulin for the continuous subcutaneous insulin external infusion pumps must be obtained through the Pharmacy Program and is not covered in the DMEPOS Program.

Louisiana Medicaid will not cover the replacement of a currently functioning insulin pump for the sole purpose of receiving the most recent insulin pump technology as this would not be medically necessary.

Louisiana Medicaid will not cover additional software or hardware required for downloading data to a device such as a personal computer, smart phone, or tablet to aid in self-management of diabetes mellitus.